-
公开(公告)号：US20180134768A1
公开(公告)日：2018-05-17
申请号：US15818472
申请日：2017-11-20
Applicant: Reef Pharmaceuticals Pty Ltd
Inventor： Damian Francis John PURCELL
IPC: C07K16/10
CPC classification number: C07K16/1063 , A61K2039/505 , A61K2039/54 , A61K2039/541 , A61P31/18 , C07K2317/12 , C07K2317/565 , C07K2317/76
Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of viral infections. More particularly, the invention relates to the use of methods and compositions for the inhibition of human immunodeficiency virus (HIV) transmission.
-
公开(公告)号：US20170121402A1
公开(公告)日：2017-05-04
申请号：US15319178
申请日：2015-06-18
Inventor： Abdessatar Sami Chtourou
IPC: C07K16/24 , A61K39/395 , A61K31/20
CPC classification number: C07K16/241 , A61K31/20 , A61K39/3955 , A61K2039/505 , A61K2039/542 , A61K2039/545 , C07K2317/12 , C07K2317/21 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition for oral delivery, including an anti tumour necrosis factor alpha (TNFα) antibody, preferably a monoclonal antibody produced in the milk of a transgenic non-human animal, and which can be combined advantageously with caprylic acid, and is preferably in a form that is suitable for targeted release of the antibody in the intestine.
-
3.发明申请THE USE OF ANTIBODIES IN TREATING HIV INFECTION AND SUPPRESSING HIV TRANSMISSION 审中-公开使用抗体治疗艾滋病毒感染和抑制艾滋病毒传播公开(公告)号：US20160039913A1
公开(公告)日：2016-02-11
申请号：US14427117
申请日：2013-09-10
Applicant: LFB USA, INC. , BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Inventor： Harry M. MEADE , Lisa CAVACINI
IPC: C07K16/10
CPC classification number: C07K16/1045 , A61K2039/505 , A61K2039/542 , A61K2039/55 , C07K16/1063 , C07K2317/12 , C07K2317/52 , C07K2317/76
Abstract: In one aspect, the disclosure provides methods of treating HIV and decreasing the chance of HIV infection in a subject, and compositions used in these methods.
Abstract translation: 一方面，本公开提供了治疗HIV并降低受试者中HIV感染机会的方法，以及用于这些方法的组合物。
-
4.发明申请ANTIBODY THERAPY FOR MODULATING FUNCTION OF INTESTINAL RECEPTORS AND METHODS OF TREATING DIABETES AND OBESITY 审中-公开用于调节功能受体的抗体治疗方法和治疗糖尿病和肥胖的方法公开(公告)号：US20150252106A1
公开(公告)日：2015-09-10
申请号：US14658569
申请日：2015-03-16
Applicant: AVAXIA BIOLOGICS, INCORPORATED
Inventor： Barbara S. Fox
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/04 , C07K16/2896 , C07K2317/12 , C07K2317/34 , C07K2317/76
Abstract: The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.
Abstract translation: 本发明提供了配制用于直接递送至包含靶向顶端肠道受体特异性抗体的患者胃肠道的药物组合物。 本发明还提供了治疗患者疾病和病症的方法，包括直接给予患者胃肠道的方法，其中本发明的组合物，其中由抗体调节靶顶端肠道受体处理该病症。
-
公开(公告)号：US08647626B2
公开(公告)日：2014-02-11
申请号：US13912569
申请日：2013-06-07
Applicant: Avaxia Biologics, Incorporated
Inventor： Barbara S. Fox
IPC: A61K39/395
CPC classification number: C07K16/241 , A61K39/3955 , A61K2039/505 , C07K2317/12 , C07K2317/20 , C07K2317/41 , C07K2317/94
Abstract: In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract.
Abstract translation: 根据本发明，提供消化道内的抗体的开发和使用。 描述了用于治疗与改变的消化道通透性相关的疾病的抗体。 描述抗体在消化道环境中具有增加的稳定性。 描述抗体对增强的易感性消化道具有增强的渗透性。
-
Patent Agency Ranking
6.发明授权Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity 有权用于调节肠道受体功能的抗体治疗和治疗糖尿病和肥胖症的方法公开(公告)号：US08268971B2
公开(公告)日：2012-09-18
申请号：US12687660
申请日：2010-01-14
Applicant: Barbara S. Fox
Inventor： Barbara S. Fox
IPC: C12P21/08 , A61K39/395 , C07K16/00
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/04 , C07K16/2896 , C07K2317/12 , C07K2317/34 , C07K2317/76
Abstract: The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.
Abstract translation: 本发明提供了配制用于直接递送至包含靶向顶端肠道受体特异性抗体的患者胃肠道的药物组合物。 本发明还提供了治疗患者疾病和病症的方法，包括直接给予患者胃肠道的方法，其中本发明的组合物，其中由抗体调节靶顶端肠道受体处理该病症。
-
7.发明授权Methods of using anti-TNF antibodies for treating radiation damage to the digestive tract 有权使用抗TNF抗体治疗消化道辐射损伤的方法公开(公告)号：US08182818B2
公开(公告)日：2012-05-22
申请号：US12753438
申请日：2010-04-02
Applicant: Barbara S. Fox
Inventor： Barbara S. Fox
IPC: A61K39/395 , A61K39/00
CPC classification number: C07K16/241 , A61K2039/505 , C07K2317/12 , C07K2317/20 , C07K2317/41 , C07K2317/522 , C07K2317/524 , C07K2317/70
Abstract: In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract.
Abstract translation: 根据本发明，提供消化道内的抗体的开发和使用。 描述了用于治疗与改变的消化道通透性相关的疾病的抗体。 描述抗体在消化道环境中具有增加的稳定性。 描述抗体对增强的易感性消化道具有增强的渗透性。
-
8.发明申请ANTIBODY THERAPY FOR TREATMENT OF DISEASES ASSOCIATED WITH GLUTEN INTOLERANCE 有权治疗与葡萄糖不良相关的疾病的抗生素治疗公开(公告)号：US20120114653A1
公开(公告)日：2012-05-10
申请号：US13290335
申请日：2011-11-07
Applicant: Barbara S. Fox
Inventor： Barbara S. Fox
IPC: A61K39/395 , A61P17/00 , A61P3/00
CPC classification number: C07K16/16 , C07K2317/12
Abstract: The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.
Abstract translation: 本发明包括用于治疗患者中与麸质不耐受相关的疾病的药物组合物和方法，其包括：向患者施用有效量的具有针对麸质或麸质衍生肽的比活性的抗体。 这些疾病包括例如乳糜泻和疱疹样皮炎。
-
9.发明授权公开(公告)号：US08158573B2
公开(公告)日：2012-04-17
申请号：US12138065
申请日：2008-06-12
Applicant: William J. McBride , David M. Goldenberg , Carl Noren , Hans J. Hansen
Inventor： William J. McBride , David M. Goldenberg , Carl Noren , Hans J. Hansen
IPC: A01N61/00
CPC classification number: A61K51/0497 , A61K47/665 , A61K51/04 , A61K51/0455 , A61K51/048 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K5/06078 , C07K5/1013 , C07K5/1016 , C07K5/1019 , C07K7/06 , C07K16/18 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K16/468 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
Abstract: Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.
Abstract translation: 公开了包含两个或多个通过间隔物或载体缀合的半抗原的化合物。 半抗原可以包括二亚乙基三胺五乙酸（DTPA），组氨酰胺 - 琥珀酰 - 谷氨酰胺（HSG）或DTPA和HSG的组合。 化合物还包括效应分子，其可以与一个或多个半抗原，间隔物/载体或两者结合。 效应分子可以通过多个键连接，包括酯键，亚氨基键，氨基键，硫键，硫代缩氨基脲键，缩氨基脲键，肟键，醚键或这些键的组合。 还公开了合成化合物的化合物和/或前体的方法。
-
公开(公告)号：US20100183632A1
公开(公告)日：2010-07-22
申请号：US12687660
申请日：2010-01-14
Applicant: Barbara S. Fox
Inventor： Barbara S. Fox
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/04 , C07K16/2896 , C07K2317/12 , C07K2317/34 , C07K2317/76
Abstract: The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.
Abstract translation: 本发明提供了配制用于直接递送至包含靶向顶端肠道受体特异性抗体的患者胃肠道的药物组合物。 本发明还提供了治疗患者疾病和病症的方法，包括直接给予患者胃肠道的方法，其中本发明的组合物，其中由抗体调节靶顶端肠道受体处理该病症。
-
-
-
-
-
-
-
-
-
Search Results
128
records
(took 0.047 seconds)
